Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Antibiotic exposure may be associated with an increased risk of early-onset colorectal cancer (CRC), according to a study from Scotland presented at ESMO GI 2021.

Antibiotic exposure tied to increased early-onset CRC risk

Best practices for gastroesophageal reflux disease in Asia-Pacific

The treatment of gastroesophageal reflux disease (GERD) continues to rely on proton pump inhibitors (PPIs), but advances in the field take account of new management options, such as antireflux surgery for reflux hypersensitivity and diaphragmatic breathing in refractory GERD or rumination, as pointed out during a lecture presented at this year’s virtual Asian Pacific Digestive Week (APDW 2021).

Best practices for gastroesophageal reflux disease in Asia-Pacific

Southeast Asia’s gastroenterologists buckle under heavy burnout burden amid COVID-19

During the coronavirus disease 2019 (COVID-19) pandemic, burnout has become prevalent among gastroenterologists in Southeast Asia, driven strongly by fears of getting infected and the stress of reduced income, according to a Singapore study presented at the recently concluded Asian Pacific Digestive Week 2021 (APDW 2021).

Southeast Asia’s gastroenterologists buckle under heavy burnout burden amid COVID-19

Altered gut microbiome as predictor of autism-spectrum disorder

Researchers from the Chinese University of Hong Kong (CUHK) have found an altered and underdeveloped composition of gut microbiome in Chinese children with autism-spectrum disorder (ASD) and identified novel bacterial markers for ASD prediction.

Altered gut microbiome as predictor of autism-spectrum disorder

Time for a shift in therapeutic approach for IBD, from stepwise to disease severity-based

Treating inflammatory bowel disease (IBD) should be individualized based on a patient’s specific situation, taking into consideration the relative efficacy, onset of speed, safety, and cost of medications, according to an expert.

Time for a shift in therapeutic approach for IBD, from stepwise to disease severity-based

ACEIs/ARBs prevent hepatocellular carcinoma, cirrhotic complications in NAFLD

Treatment with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) results in a reduced risk of hepatocellular carcinoma (HCC) and cirrhotic complications in patients with nonalcoholic fatty liver disease (NAFLD), particularly among those with chronic kidney disease (CKD), according to a study presented at the virtual Asian Pacific Digestive Disease Week (APDW) 2021.

ACEIs/ARBs prevent hepatocellular carcinoma, cirrhotic complications in NAFLD

Oral n-acetyl cysteine may prevent post-ERCP acute pancreatitis

Use of the oral antioxidant and anti-inflammatory n-acetyl cysteine (NAC) – be it alone or in combination with rectal indomethacin – may prevent the occurrence of post-ERCP* acute pancreatitis (PEAP), according to findings from a study presented at APDW 2021.

Oral n-acetyl cysteine may prevent post-ERCP acute pancreatitis

Second-line tislelizumab improves OS in advanced/metastatic ESCC in European/North American subgroup

Second-line treatment with tislelizumab improves overall survival (OS) in patients from Europe/North America (EU/NA) with advanced or metastatic oesophageal squamous cell carcinoma (ESCC) compared with chemotherapy, according to subgroup analysis of the RATIONALE 302* study presented at ESMO GI 2021.

Second-line tislelizumab improves OS in advanced/metastatic ESCC in European/North American subgroup